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Resveratrol (RSV) is a natural polyphenol produced by plants and is proposed to have multiple beneficial effects on health. In recent years, the interest in this molecule has increased nearly exponentially following the major findings that RSV (I) is chemo-preventive in some cancer models, (II) is cardio-protective and (III) has positive effects on metabolism in mammals and increases lifespan in lower organisms. Mechanistic target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism and angiogenesis. As a part of the mTORC1 and mTORC2 complexes, the mTOR kinase plays a key role in several pathways involved in cancer and metabolic diseases. Recent studies suggest that modulation of the mTOR signalling pathway could play an important role in mediating the beneficial effects of RSV. Therefore, this review summarises the current findings regarding RSV and its inhibition/activation of the proteins in the mTOR pathway, and thereby propose the proteins of the mTOR cascade to be primary targets for RSV. RSV affects many different targets related to mTOR, and it is not clear which is most relevant. However, most frequently, RSV is found to inhibit the activity of the mTOR pathway proteins, and to activate AMPK and LKB1, which can suppress mTOR signalling. Thus, it appears that RSV plays a role in modulation of proteins of the mTOR pathway although more research is still needed to fully understand the interaction.
The mechanistic target of rapamycin (mTOR) pathway plays a crucial role in many human diseases, including cancer, diabetes and immune disorders. Intriguingly, these diseases are associated with aberrant hyperactivity of the mTOR pathway, which makes inhibitors of mTOR potentially effective therapeutics. One of the most exciting developments in recent years is the discovery that mTOR is a key regulator of lifespan in eukaryotes and contributes significantly to multiple age-related diseases (Ref. 1). These observations emphasise the importance of identifying and understanding the functional components of the mTOR signalling network, and recent studies have provided significant insights into the molecular architecture of the mTOR pathway (Refs 2, 3). Simultaneously, there has been a growing focus on the compound resveratrol (RSV), which is reported to have antioxidant and antiinflammatory effects, anti-cancer effects and beneficial effects on metabolism. The aim of present paper is to review the emerging evidence for effects of RSV on the mTOR pathway. RSV modulates a number of specific proteins in the mTOR pathway and these interactions may have important implications for human health.
Resveratrol

RSV (3,4
′ ,5-trihydroxy-trans-stilbene) is a naturally occurring polyphenol (Fig. 1) . RSV is found in low concentrations in more than 70 plant species including grapes, cranberries and peanuts, and also in a number of herbal remedies (Ref. 4) . RSV from grapes is efficiently extracted during the process of winemaking, and it has been speculated that red wine, in particular, may be the most important dietary source of RSV. Notably, the RSV doses available in supplements and used in many clinical trials are 2-3 orders of magnitude beyond what could be obtained from the diet (Ref. 5) .
Many of the health benefits of RSV are proposed to be mediated at least partly by suppression of low-grade inflammation, which is important for prevention of cancer, coronary heart diseases, diabetes and neurodegeneration (Refs 6, 7, 8) . Similarly, variations in the cellular redox status are closely related to several diseases and are often found linked to the anti-inflammatory effect of RSV. Multiple biochemical and molecular actions, including changes in cell proliferation, apoptosis and angiogenesis, as well as suppression of DNA damage and inhibition of factors specific to metastasis are all proposed to contribute to RSV's effects against precancerous or cancer cells (Refs 9, 10). The alteration of xenobiotic metabolism by RSV probably plays a significant role in its cancer-preventive effect, but may also have an impact on drug metabolism. The induction of mitochondrial activity by RSV appears to be crucial in obesity/ diabetes, but may also be important in its effects on longevity and influence Ca 2+ uptake and signalling (Ref. 11) . Suppression of adipogenesis and stimulation of adipocyte lipolysis by RSV are significant when effect on obesity and diabetes are considered (Ref. 12) . Neuroprotection by RSV is likely caused by modulation of glutamate metabolism (Ref. 13) . RSV also stimulates osteogenesis and may stimulate bone formation or slow the progression of osteoporosis (Refs 14, 15) . During the last decade, RSV has been revealed to possess a fascinating spectrum of pharmacologic properties which could be useful in human medicine (Refs 5, 16) .
Multiple human clinical trials have been completed with RSV, and are summarised in Vang in 2013 (Ref. 17) . However, the majority of experimental data that are available is from studies employing various animal models or human cells. Most of the human trials have been designed to evaluate the therapeutic effect of RSV rather than the disease-preventing effect, and most have involved a very short duration of treatment (Refs 17, 18) . Therefore, further studies in animal models similar to humans as well as in humans are needed in order to evaluate the chronic effect of RSV and to verify the lack of adverse effects in humans (Refs 5, 16) .
It is important to note that often there are discrepancies between the doses of RSV used in cells, and the levels that are obtained in vivo. For example, many studies with RSV that show an impact on mTOR signalling are performed at concentrations in the range of 10-100 μM (Ref. 19) . In contrast, a single 25 mg dose of RSV, corresponding to high red wine consumption, resulted in marginal levels of plasma RSV in human subjects, and a 5 g bolus dose produced a transient peak of only 2.4 μM (Ref. 20) . When lower concentrations corresponding to plasma levels are used on cells, outcomes are variable, and often no effect is detected (Ref. 17) . Leontieva et al. show no inhibition of mTOR activity by RSV at physiological levels in an in vitro experiment (Ref. 21) , which should be taken into account when interpreting results obtained using higher concentrations. RSV is well absorbed in the human gastrointestinal tract, although bioavailability of RSV in the human body is very limited because of rapid metabolism. In a phosphorylation events. Specifically, mTORC1 contains mTOR phosphorylated predominantly on S2448, whereas mTORC2 contains mTOR phosphorylated predominantly on S2481 (Ref. 32) , although it should be noted that these marks are not completely exclusive (Ref. 33) . Under RSV treatment, mTOR phosphorylation of mTOR at serine 2448 was inhibited, whereas the phosphorylation of mTOR at serine 2481 was increased with low-dose RSV, but attenuated with high-dose RSV (Ref. 21 ).
mTORC1 and mTORC2 have different targets and modes of regulation: mTORC1 is responsible for sensing nutrient signals and controlling cell growth (size) and proliferation in part by phosphorylating the downstream S6 serine/ threonine kinase 1 (S6K1) and the eIF-4E-binding protein 1 (4E-BP1). mTORC2 is involved in the organisation of actin and thereby determining the shape of the cell. It also modulates cell survival in response to growth factors by phosphorylating its downstream effectors AKT, also known as protein kinase B (PKB), which plays a key role in multiple cellular processes such as glucose metabolism, cell proliferation, apoptosis, transcription and cell migration and serum/ glucocorticoid regulated kinase 1 (SGK1) (Ref. 26).
Step-by-step description of the mTOR pathway mTORC1 signalling regulates translation initiation by integrating several different inputs from nutrients including amino acids, as well as insulin and other hormones and growth factors activating the cell surface receptors, which activate the PI3 K/AKT signalling cascade (Fig. 3 ). mTORC2 serves as one of the kinases for AKT. Activated AKT phosphorylates TSC2 and destabilises the TSC1/2 complex (tuberous sclerosis complex), thus promoting the activation of mTORC1 because of the lack of inhibition of Rheb by TSC1/TSC2. Interestingly, this signalling to mTORC1 by AKT is largely intact in the absence of mTORC2, despite the fact that other AKT functions are disrupted (Ref. 40) . On the other hand, Adenosine 5-monophosphateactivated protein kinase (AMPK) is modulated by the energy status (the AMP:ATP ratio) and upstream kinases including LKB1, and AMPK activates the TSC1/2 complex to repress mTORC1 signalling (Ref. 25) . REDD1 protein (reregulated in development and DNA damage responses 1) is induced upon hypoxia, and also inhibits mTORC1 through activation of the TSC1/2 complex (not shown in Fig. 3 ). mTORC1 mediates the phosphorylation of 4E-BP1, S6K1 and eIF4G. Once activated, S6K1 phosphorylates ribosomal protein S6 and eIF4B. The net effect of these actions is an increase in translation. Phosphatidylinositol-3-kinase (PI3 K) is a lipid kinase, when activated, generates phosphatidylinositol-3,-4,-5-trisphosphate (PIP3). PIP3 is a second messenger essential for translocation of AKT to the plasma membrane. The PI3 K/AKT signalling pathway is activated by class IA PI3 K, wherein its regulatory subunits mediate activation of its p110 catalytic subunits by direct interaction with phosphorylated tyrosine residues of the activated receptors or adaptor proteins. AKT is phosphorylated and activated by phosphoinositide dependent kinase 1 (PDK1) (Fig. 3) Fig. 3) , and others may exist. AMPK targets several proteins involved in cellular energy balance, including a key regulator of the switch between fatty acid biosynthesis and oxidation, acetyl-CoA carboxylase (ACC).
The AMPK pathway is linked to cell proliferation and tumour growth through the mTOR pathway. The calcium/CaMKKβ/AMPK signalling pathway controls mechanisms related to protein degradation through inhibition of mTOR signalling and the induction of autophagy (Ref. 48) . Inflammatory stimuli induce the production of reactive oxygen species Modulation of mTOR cascade proteins by RSV RSV's effect on specific proteins in the mTOR pathway Many experiments have been carried out to define the effect of RSV on the mTOR pathway proteins and generally, the reported effects have been either down-regulated or no change (Fig. 4) . Here, we present RSV's effects on the specific proteins in the mTOR pathway, including a very brief description of SIRT1's role in the regulation of the mTOR cascade. The inhibitory effects of RSV are also represented in Figure 3 .
PI3 K/AKT inhibition by RSV
The inhibitory effects of RSV on the PI3 K/ AKT signalling pathway and mTOR further down have been observed in multiple cell lines. Kueck et al. showed that RSV inhibited AKT phosphorylation in a dose-and time-dependent manner, which could provide a SIRT1-independent pathway to account for an observed decrease in glucose uptake (Ref. Waite et al. investigated the ability of RSV to regulate PTEN protein levels in a breast cancer cell line. They observed that RSV increased PTEN protein levels and caused an apparent decrease in the level of phosphorylated AKT (Refs 53, 68, 69). A combination of curcumin (a proposed mTOR inhibitor) and RSV effectively inhibited cell growth and induced apoptosis in in vitro studies. Murine PTEN-Cap8 prostate cancer cells showed a decreased cell growth when exposed to 10 μM RSV or curcumin but in combination (5 μM of each), the effect was significantly stronger than either RSV or curcumin alone. In PTEN-Cap8 cells, RSV was found to inhibit AKT and mTOR (Ref. 
AMPK-dependent effects
There is considerable debate about the mechanism by which RSV regulated SIRT1. Some show that a direct activation of SIRT1 by RSV is an in vitro 
4EBP1 inhibition
There has been some interest in signalling via mTORC1 and previous works demonstrate that the metabolic actions of RSV require AMPK (Ref. 
S6K1 inhibition
A large-scale in vitro kinase screen identified S6K1 as a direct target of RSV, raising the possibility that the beneficial effects of RSV are because of modulation of S6K1 activity. In addition, it was shown that inhibition of S6K1 by RSV can prevent the full induction of autophagy in mammalian cells. This process is often used by cells to promote survivals under adverse conditions, for example, stress signals and nutrient deprivation. In contrast to the activation of the autophagy pathway observed in tumour cells in complete media, RSV markedly inhibits the starvation-induced autophagy response (Ref. 
DEPTOR inhibition
DEPTOR is regarded as a negative regulator of the mTORC1 and mTORC2 signalling pathways and inhibits the kinase activity of both complexes. DEPTOR regulates protein synthesis and cell growth by inhibiting the ability of mTORC1 to phosphorylate downstream target proteins such as ribosomal S6K1 and 4E-BP1. DEPTOR is involved in regulation of apoptosis and the cell size (Refs 2, 28). RSV was recently shown to increase the association between mTOR and DEPTOR, providing further evidence that DEPTOR could be involved in the RSV-induced 
Summary
Overall, the evidence presented herein supports the conclusion that RSV can inhibit the mTOR pathway. The mTOR cascade plays a crucial role in the determination of cell proliferation and growth, balancing the input of growth factors, energy and amino acids. Therefore, inhibition of mTOR has important implications for both ageing and cancer research, which is supported by the observation that this pathway is aberrantly activated in many human cancers (Refs 104, 105). Thus, approaches to block the pathway are being actively pursued in many laboratories and pharmaceutical companies. Because mTOR is regulated by multiple factors, there are a number of target proteins for which intervention would be predicted to lower mTOR activity and have an impact on cancer, and possibly other age-related diseases.
Hahn-Windgassen et al. suggest that AKT/PKB can signal via mTORC1 by decreasing the AMP:ATP ratio and thus preventing AMPK from activating TSC1/TSC2 (Ref. 106 ). In addition, AKT/PKB regulates the influx of nutrients that activate the mTORC1 pathway (Ref. 107) . It has been suggested that the regulation of mTORC1-mediated fat metabolism involves signalling through S6K1 and 4E-BP1. More direct evidence of mTORC1-S6K1 pathway's role in fat metabolism has been obtained from the S6K1-mutant mice used by Um et al. (Ref. 108) . These observations indicate that S6K1 and 4E-BP1 might be novel therapeutic targets for the development of antiobesity drugs, and as presented in Figures 3 and  4 , RSV inhibits S6K1/2 and 4EB-P1. Even though 4E-BP1 is one of the best characterised downstream effectors of mTORC1, data concerning its interactions with RSV are limited. Further studies are required to eliminate or confirm 4E-BP1 as a relevant target for RSV in vivo.
RSV stimulates AMPK activation likely by activation of the AMPK kinase LKB1; however, its activation is independent of SIRT1. Although the exact mechanism of RSV-mediated AMPK activation is unclear, there are four proposed mechanisms: inhibition of complex I, SIRT1-dependent LKB1 activation, SIRT1-independent LKB1 activation and PDE inhibition (Ref. 79) . Because both SIRT1 and AMPK are involved in responses to metabolic stress, it will be interesting to determine whether there are additional interactions between these two protein families in neurons and other cells (Refs 109, 110 ). These observations coupled with the demonstration that RSV can activate AMPK and lead to inhibition of ACC suggest that many calorie restriction mimetic actions of RSV might depend on the AMPK cascade. Indeed, the multiple beneficial effects of RSV may be because of its ability to alter the activity of multiple proteins involved in the cellular response to stress (i.e. SIRT1 and AMPK). The effect of RSV on AMPK is mediated via LKB1 and findings indicate that RSV can prevent inhibition of the LKB1/AMPK signalling pathway of mTORC1. Whether RSV has a direct effect on LKB1 or is mediated via another effector molecule is currently unknown (Ref. 89) . Several research groups have reported that LKB1 is a key upstream kinase for AMPK (Refs 111, 112, 113) .
Evidence indicates that SIRT1 plays a role in the inhibition of mTORC1 signalling by RSV, but exactly where SIRT1 influences the pathway, and how relevant these mechanisms are in vivo, still need to be investigated. Experiments by Demidenko and Blagosklonny in 2009 showed that low concentrations of RSV do not inhibit S6 phosphorylation in culture. However, normal cells in the organism might be more sensitive to RSV. So, a crucial question is whether RSV can inhibit S6 phosphorylation in adipocytes, hepatocytes, muscle and other relevant cell types in the organism (Ref. 36) . DEPTOR is an additional protein in the mTOR complexes, which is regulated by RSV (Ref. 34) . The mechanism by which RSV promotes the binding of DEPTOR to mTOR complexes remains unknown, and could be because of direct binding or effects on upstream pathways. Therefore, there are likely to be multiple important mechanisms by which RSV negatively regulates mTOR signalling and function.
Perspectives
Over the last decade, knowledge of the mTOR signalling pathway has increased greatly, enabling researchers to better understand the mechanism of diseases such as cancer and type II diabetes. Despite these advances, our understanding of this signalling network is far from complete and many important questions remain to be answered. For example, how is mTORC2 regulated and which biological processes does it control? How are the mTORC1 and mTORC2 signalling pathways integrated with each other? What are the functions of these complexes in adult tissues and organs and what are the implications of their dysfunction or dys-regulation in health and disease? Are there additional mTOR complexes that regulate other biological processes? (Ref. 29) . And how will RSV affect these pathways?
As RSV enters clinical trials, and becomes more widely available as a supplement, it becomes even more important to understand the mechanisms that lead to both desirable and undesirable effects in vivo. Research into the direct targets and downstream effects of RSV will advance our understanding of cellular biology and help to develop RSV or more specific compounds as potential therapeutic avenues to treat human diseases. Many challenges remain concerning the optimal dosage, since the amounts used in most cell and animal experiments may not be applicable to humans, and multiple distinct targets with differing localisations and sensitivities to the drug are likely to be relevant to health.
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